|Day Low/High||175.38 / 180.25|
|52 Wk Low/High||151.80 / 195.81|
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
These stocks are down some 20% over the last 30 months and look ripe for a rise.
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the results of a Phase 3 study of ORKAMBI ® (lumacaftor/ivacaftor) in children with cystic fibrosis (CF) ages 6 through 11 who have two copies of...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8 th at 3:30 p.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The development of QR-010 is still early but Thursday's preliminary study results were encouraging enough to boost ProQR's stock price.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of long-term data demonstrating that ORKAMBI ® (lumacaftor/ivacaftor) and KALYDECO ® (ivacaftor) show the potential to...
Vertex Pharma (VRTX) reported lower-than-expected results for the third quarter late yesterday.
More about Vertex's Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2016 and reviewed recent progress with its approved and investigational cystic...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple combination regimens with...
Illumina fell 24% on news that it was cutting revenue guidance.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2016 financial results on Tuesday, October 25, 2016 after the financial markets close.
Vertex Pharmaceuticals shares are down 31% year to date. Investors are wondering if they should hang on, buy or wait.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at The Morgan Stanley Global Healthcare Conference in New York, NY on Wednesday, September 14 th at 11:40 a.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Vertex Pharmaceuticals, Inc. has taken over the #81 spot from Starbucks Corp.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies...
This is where a lot of money has been parked in the last year.
The company also could look to acquire a smaller biotech company, though likely not Medivation.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMOT, ANGI, CBT, ELY, FTAI, GNBC, LOGM, NCR, SIX, SKUL, SLAB, SNY, SONS, TRK, TRN, UFS, VRTX, WES, ZNGA Downgrades: AF, BA, TER, WEX Initiations: FSV Read on to get TheStreet Quant Ratings' detailed report:
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2016 and reviewed recent progress with its approved and investigational cystic fibrosis...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close.
TheStreet highlights 3 stocks pushing the health care sector lower today.
A dovish Federal Reserve in June pushes equities, crude to close around session highs.
Stocks add to gains by late afternoon Wednesday after the Federal Reserve's June meeting minutes confirm members' prudent approach to monetary policy.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Moderna Therapeutics today announced that the two companies have entered into an exclusive research collaboration and licensing agreement aimed at the discovery...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.